Spyre Therapeutics, Inc. Common Stock (SYRE) Stock
NASDAQ · SYRE
90.25
Fundamentals
Market cap
$7.96B
Price / Earnings ratio
-45.7x
Price / Sales ratio
N/A
Price / Book ratio
7.4x
Return on assets
-0.3%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Spyre Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees125
CEODr. Cameron Turtle DPHIL, Ph.D.
IPO DateApr 6, 2016
HeadquartersWaltham, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | CEO & Director | 1990 |
| Mr. Scott L. Burrows | Chief Financial Officer | 1977 |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary | 1983 |
| Dr. Sheldon Sloan M.B.E., M.D. | Chief Medical Officer | 1959 |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations | — |
| Mr. Brian Connolly | Chief Technical Officer | — |
| Mr. Eric McIntyre | Senior Vice President of Finance & Investor Relations | — |
| Mr. James Myers | Senior Vice President of Quality & Compliance | — |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development | — |
| Ms. Melissa Cooper | Senior Vice President of People | — |
Fundamentals
Valuation
Market cap$7.96B
Price-to-sales ratioN/A
Price-to-book value7.42
Price-earnings ratio-45.70
Return on Equity-31.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.99
Income Statement
Average volume1,191,133
EBITDA$-179.44M
1 year high (52w)$110.18
1 year low (52w)$14.51
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



